Mark Dresser Elected First Openly-LGBTQ+ President of American Society for Clinical Pharmacology and Therapeutics
Appointment furthers ASCPT's commitment to diversity, equity, and inclusion
We’re proud to share that Mark Dresser, Gilead’s Senior Vice President of Biomarker Sciences and Clinical Pharmacology, has been elected President of the American Society for Clinical Pharmacology & Therapeutics (ASCPT). As the first openly LGBTQ+ president in ASCPT’s 122-year history, Mark is an exemplary leader for our industry – and one who advocates for LGBTQ+ equality in STEM and furthers inclusion within the scientific community.
About Gilead Sciences
Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The company strives to transform and simplify care for people with life-threatening illnesses around the world. Gilead has operations in more than 35 countries worldwide, with headquarters in Foster City, California.
Originally Published by Gilead Sciences
